HAE
Haemonetics CorporationNYSEHealthcare$56.83+1.05%ClosedMarket Cap: $2.66B
As of 2026-04-06
Valuation
P/E (TTM)
15.16
PEG
0.43
P/B
3.00
P/S
2.08
EV/EBITDA
9.58
DCF Value
$565.51
FCF Yield
11.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
58.5%
Operating Margin
19.2%
Net Margin
13.3%
ROE
20.3%
ROA
7.0%
ROIC
8.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $339.0M | 56.5% | $69.6M | $44.7M | $0.95 | — |
| Q2 2026 | $327.3M | 59.5% | $58.5M | $38.7M | $0.81 | — |
| Q1 2026 | $321.4M | 59.7% | $53.9M | $34.0M | $0.70 | — |
| Q4 2025 | $330.6M | 58.4% | $71.3M | $58.0M | $1.17 | — |
| FY 2025 | $1.36B | 57.2% | $221.8M | $167.7M | $3.31 | — |
| Q3 2025 | $348.5M | 57.4% | $59.0M | $37.5M | $0.74 | — |
| Q2 2025 | $345.5M | 55.3% | $51.7M | $33.8M | $0.66 | — |
| Q1 2025 | $336.2M | 53.3% | $39.8M | $38.4M | $0.74 | — |
| Q4 2024 | $343.3M | 55.0% | $29.9M | $20.4M | $0.40 | — |
| FY 2024 | $1.31B | 54.4% | $164.9M | $117.6M | $2.29 | — |
| Q3 2024 | $336.3M | 55.0% | $46.0M | $31.2M | $0.61 | — |
| Q2 2024 | $318.2M | 53.6% | $35.3M | $24.9M | $0.48 | — |